Develops GDF-15-targeting immunotherapies for cancer.
| Date | Round | Amount |
|---|---|---|
| Nov 2022 | Series C Bavaria-based biotech CatalYm raised a EUR50M Series C co-led by Brandon Capital and Jeito Capital, with Forbion, Novartis Venture Fund and others returning. | $50M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.